UCART19: First in Man Proof of Concept to be Presented Cellectis announced that Great Ormond Street Hospital and University College London will present encouraging data from a first in man clinical use of UCART19. [Press release from Cellectis Inc. discussing research to be presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release Compugen Presents Translational Study Results Supporting CGEN-15001 for the Treatment of Rheumatoid Arthritis Compugen Ltd. has disclosed recent results from a translational study supporting the potential treatment of rheumatoid arthritis with CGEN-15001. CGEN-15001 is an Fc fusion protein based on one of the multiple novel immune checkpoint candidates discovered by the company. [Press release from Compugen Ltd. (Business Wire) discussing research to be presented at the 2015 ACR/ARHP Annual Meeting, San Francisco] Press Release Janssen Data Presentations Showcase Commitment to Rheumatologic Diseases Janssen Biotech, Inc. announced that more than 35 abstracts from the Janssen Pharmaceutical Companies will be presented. [Press release from Janssen Biotech, Inc. discussing research to be presented at the 2015 ACR/ARHP Annual Meeting, San Francisco] Press Release OncoMed Presents Data from Brontictuzumab, Vantictumab and Anti-DLL4/VEGF Bispecific Programs Data from three posters covered Phase Ia safety, biomarker and anti-tumor activity of brontictuzumab, novel biomarker discoveries related to vantictumab in non-small cell lung cancer and preclinical characterization of safety and efficacy for anti-DLL4/VEGF bispecific. [Press release from OncoMed Pharmaceuticals Inc. discussing research presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston] Press Release Data Demonstrating that SEPREHVIR Combines Synergistically with Anti-PD-1 Immune Checkpoint Inhibitor to Be Presented Entitled “Checkpoint Blockade Enhances Oncolytic Herpes Virotherapy in Immunosuppressive Sarcoma Models”, the poster describes marked synergy between SEPREHVIR and an anti-PD-1 antibody in an immunocompetent, PD-L1 positive rhabdomyosarcoma model. [Press release from Virttu Biologics discussing research to be presented at AACR’s Advances in Pediatric Cancer Research, Fort Lauderdale] Press Release Aduro Biotech Announces Five Poster Presentations at the Society of Immunotherapy of Cancer Annual Meeting Aduro Biotech, Inc. announced five posters highlighting ongoing clinical trials and pre-clinical programs investigating its novel immunotherapies in development for the treatment of cancer were presented. [Press release from Aduro Biotech, Inc. discussing research presented at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC), National Harbor] Press Release Advaxis Presents New Data Featuring Its Lm Technology™ Advaxis, Inc. presented a poster featuring clinical development advances with its Lm Technology™. The study evaluated whether axalimogene filolisbac could be dosed at higher levels than previous studies conducted by Advaxis in patients with persistent or recurrent metastatic carcinoma of the cervix. [Press release from Advaxis, Inc. discussing research presented at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC), National Harbor] Press Release Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 Galena Biopharma, Inc. announced that data from the company’s GALE-301 and GALE-302 clinical programs were presented. The data presented was on the primary vaccine series from a randomized Phase Ib trial with GALE-301 and GALE-302 that are folate binding protein-derived peptides. [Press release from Galena Biopharma, Inc. discussing research presented at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC), National Harbor] Press Release From our sponsor: Learn how ex vivo models drive progress in HIV research. Read the research profiles. |